{"id":"NCT01766076","sponsor":"Makerere University","briefTitle":"Atorvastatin for HAART Suboptimal Responders","officialTitle":"Use of Atorvastatin as Adjuvant Therapy Among Suboptimal Responders to Antiretroviral Therapy in an African Cohort of HAART-treated Adults: A Randomised Controlled Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2014-02","completion":"2014-03","firstPosted":"2013-01-11","resultsPosted":"2015-05-21","lastUpdate":"2015-05-21"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acquired Immune Deficiency Syndrome Virus"],"interventions":[{"type":"OTHER","name":"atorvastatin, Lipitor®","otherNames":["Lipitor®"]},{"type":"DRUG","name":"Placebo","otherNames":["atorvastatin placebo"]}],"arms":[{"label":"atorvastatin, Lipitor®","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"We hypothesise that atorvastatin changes immune activation among HAART-treated adults with suboptimal cluster cell differentiation 4 (CD4) recovery by 25%","primaryOutcome":{"measure":"Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily","timeFrame":"12 weeks","effectByArm":[{"arm":"Atorvastatin","deltaMin":60,"sd":null},{"arm":"Placebo","deltaMin":21,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21325137","21299909"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Myalgia","Chest pain","headache","Joint pains","backache"]}}